Intratumoral PH-762 for Cutaneous Carcinoma
← catalyst calendarSponsored by Phio Pharmaceuticals Inc. (industry) · PHIO — their whole pipeline →. With Prosoft Clinical.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-07 | actual | When the study began enrolling |
| Primary completion | 2025-12-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Squamous Cell Carcinoma of the Skin
- Malignant Melanoma of Skin
- Merkel Cell Carcinoma of Skin
Intervention
- Drug: PH-762
Primary outcome
what the primary-completion date above is the date OFAdverse Events
measured 16 weeks
Publications
- PMID 39697325 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PHIO's whole pipeline · Catalyst calendar · Every registered study · What changed